ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC

IO, Chemo-Free Strategy

 
• By Dexter Jie Yan
  
set sail
GenFleet sets sail in first-line KRAS G12C-mutated NSCLC with novel combo strategy excluding PD-1s • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia